#### IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

International Application No.	:	PCT/EP2004/005546
International Filing Date	:	24 May 2004 (24.05.2004)
Priority Date(s) Claimed	:	16 June 2003 (16.06.2003)
Applicant(s) (DO/EO/US)	:	Timo HEINRICH, et al.

Title: INDOLE DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS

### INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

#### Timing and Fees

$\boxtimes$		37 C.F.R. § 1.97(b), no fee or statement is required for filing this information sure statement is filed:
		within three months of the filing date of a national application other than a CPA under $\S$ 1.53(d);
	$\boxtimes$	within three months of the actual filing date of the national phase of a PCT application; $\mbox{OR}$
		before the mailing of a first substantive office action (including after filing of an RCE).

a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and

Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods

specified in 37 C.F.R. § 1.97(b), but before the mailing date of:

		is acco	mpanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. $\S$ 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
		a final	action under 37 C.F.R. § 1.113;
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);
		OR a r	notice of allowance under 37 C.F.R. § 1.311;
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 0 under 37 C.F.R. § 1.17(p).
Statem	nents Ur	ider 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	<u>ls</u>	
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).
	$\boxtimes$		of materials listed but not attached were cited in an international search dated August 19, 2004.
		Not re	quired by 37 CFR § 1.98.
		Copies	s of the materials listed are attached (except for the foregoing).

		_	
Non-E	inglish	Languag	e References
			glish-language search report or equivalent paper from a foreign patent is provided indicating the relevance of the cited reference(s).
			ign-language search report from a foreign patent office is provided, and nt parts are translated substantively below:
		X = Y = A =	document of particular relevance when it is taken alone document of particular relevance when it is combined with another such document document defining the general state of the art
		O =	non-written disclosure
		P =	intercalated document
		T =	document cited to understand the theory or principle underlying the invention
		E =	patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D =	cited in the application
		L=	cited for another reason
		&=	publication of member of same patent family
	$\boxtimes$	Transla	ation of other relevant information on foreign search report
		"Verbi examp means means table, a in the a	search report, "Seite" means page, "Seiten" means pages, ndungen der Formel" means Figure of formula, "Beispele" means les, and "das ganze Dokument" means the entire document, "Spalte" column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" example, "Zusammenfassung" means summary, and "Tabelle" means und "Tabellen" means tables "in der Anmeldung erwaehnt" means cied application, "Schema" means scheme, "und" means and, "Absatz" break, "Abildung" means figure.
Other	Informa	ation	
Paym	ent of F	ees Due	(If Any):
	A che	ck for \$	covering the fee identified above is attached.

Please charge to Deposit Account No. 13-3402 \$\_\_\_\_\_ for the fee identified above.

### 10/560737 IAPPROCOPCT/PTD 15 DEC 2005.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Anthony J Zelano, Reg. No. 27,969 Attorney Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-3100

Date: December 15, 2005

AJZ:ssr

## 10/560737

# IAPO Rec'd PCT/PTO 15 DEC 2000

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

	Under the Paperwoo	rk Redu	ction Act of 1995, no persons		demark Office: U.S. DEPARTMENT OF COMMER of information unless it contains a valid OMB control numb	
Substitute	for form 1449A/PTO			Complete if Known		
				Application Number	USNP of PCT/EP2004/005546	
INFO	RMATION	DIS	CLOSURE	Filing Date	24 May 2004 (24.05.2004)	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Timo HEINRICH, et al.	
				Group Art Unit	unknown	
	(use as many she	ets as	necessary)	Exeminer Neme	unknown	
01		.,			MEDOIC 0400	

			U.S. F	ATENT DOCUMENTS	
Examiner Initials *	Cite No.1	U.S. Patent Docum	ent Kind Code <sup>2</sup> (if known)	Name of Petentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	001	5,532,241	Α	BOTTCHER, ET AL.	07-02-1996
	002	6,476,035	B1	MOLTZEN, ET AL.	11-05-2002
	003	5,002,948	Α	PERREGAARD, ET AL.	03-26-1991
			ļ		
			1		

				<b>FOREIG</b>	N PATENT DOCUMENTS			
Examiner Initiels*	Cite No.1			Kind Code <sup>5</sup> (If known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevent Passages or Relevant Figures Appear	T*
		-WO-	2004/054072		BOSTICHER, STAL	07-01-2004		
	005	EP	0 648 767	Α	MERCK PATENT GMBH	04-19-1995		001
	006	wo	99/05140	A	MIKKELSEN, ET AL.	02-04-1999		002
	-007	₩0-	-02/003606-	———	DOETTCHEN, ET AL.	10-24-2002		
	008	EP	0 376 607	Α	LUNDBECK & CO AS H	07-04-1990		003

Signature	7140DIC OLITOIII	Considered	01/01/2000
***************************************			

Date

01/07/2008

/Noble Jarrell/

and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Union classon designation number. <sup>2</sup> See structed Kinds of U.S. Plant Documents. <sup>2</sup> Exter Office that issued the document, by the two-little crode (VMPC) Standard ST3. <sup>1</sup> For Japanese planted occuments, be existed in the year of the riespy of the Employment precede the series in unimber of the patient document. <sup>2</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. <sup>1</sup> 16 F passible. <sup>2</sup> Applicant is to place a check mark here of English in Jaquage Translation is altached. Number refers to English in Jaquage corresponding firshly member.

Burden Hour Statement This form is estimated to take 2.0 hours to compete Time will very depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. U.S. Patrio Officer. Vis. Patrio Officer.

## 10/560737 (AP9 Rec'd PCT/PTO 15 DEC 2005

Please type a plus sign (+) insida this box	<b>→</b> [+	1

PTO/SB/08A (08-00)

Approved for use through 103 12022, OMB 065-b031 U.S. Patient and Trademark Office U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substituta fo	or form 1449A/PTC	)		Complete if Known			
MEGE	NA A TION	DIC.	CL OCUPE	Application Number	USNP of PCT/EP2004/005546		
			CLOSURE	Filing Date	24 May 2004 (24.05.2004)		
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Timo HEINRICH, et al.		
				Group Art Unit	unknown		
(4	ise as many she	ets as	necessary)	Examiner Name	unknown		
Sheet	2	of	2	Attorney Docket Number MERCK-3100			

1.50	4000	NON PATENT LITERATURE DOCUMENTS	12.
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the litem (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т 2
	000	HEWITT, NICOLA J. ET AL: "STUDIES COMPARING IN VIVO: IN VITRO METABOLISM OF THREE PHARMACEUTICAL COMPOUNDS IN RATS, DOGS, MONKEYS, AND HUMANS OF THE PHARMACEUTICAL COMPOUNDS IN RATS, DOGS, MONKEYS, AND COLLAGEN OF THE PHARMACE AND COLLAGEN OF THE PHARMACE AND COLLAGEN OF THE PHARMACE	
		IMMOBILIZED HEPATOCYTE CULTURES* DRUG METABOLISM AND DISPOSITION, 29(7), 1042-1050 CODEN: DMDSAI; ISSN: 0090-9556	

Examiner Signature	/Noble Jarrell/	Date Considered	01/07/2008	]

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached,

Burdan Hox Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete the form should be sent to the Chief Information Officer. U.S. Pleatent and Trademark

Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O.
Box 1450, Alexandric, V. 22313-1450.